Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

Dolutegravir 50 mg is registered for use in children weighing 20–40 kg. This approval is based on data from an African paediatric cohort, and no pharmacokinetic data was available from children outside of Africa. This study provides further evidence of the effective use of dolutegravir 50 mg in chil...

Descripción completa

Detalles Bibliográficos
Autores principales: Waalewijn, Hylke, Stol, Kim, van der Knaap, Linda, Fraaij, Pieter L.A., Vermont, Clementien, van Rossum, Annemarie M.C., Strik-Albers, Riet, Burger, David M., Svensson, Elin M., Colbers, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612713/
https://www.ncbi.nlm.nih.gov/pubmed/36111542
http://dx.doi.org/10.1097/QAD.0000000000003350
Descripción
Sumario:Dolutegravir 50 mg is registered for use in children weighing 20–40 kg. This approval is based on data from an African paediatric cohort, and no pharmacokinetic data was available from children outside of Africa. This study provides further evidence of the effective use of dolutegravir 50 mg in children weighing 20 to 40 kg by showing that concentration data gathered in clinical practice shows adequate concentration levels in Dutch children without a safety signal.

Ejemplares similares